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There is a limited understanding about the impact of rare protein-truncating variants acrossmultiple phenotypes.We explore the impact
of this class of variants on 13 quantitative traits and 10 diseases using whole-exome sequencing data from 100,296 individuals. Protein-
truncating variants in genes intolerant to this class of mutations increased risk of autism, schizophrenia, bipolar disorder, intellectual
disability, and ADHD. In individuals without these disorders, there was an association with shorter height, lower education, increased
hospitalization, and reduced age at enrollment. Gene sets implicated fromGWASs did not show a significant protein-truncating variants
burden beyond what was captured by establishedMendelian genes. In conclusion, we provide a thorough investigation of the impact of
rare deleterious coding variants on complex traits, suggesting widespread pleiotropic risk.Protein-truncating variants (PTVs) are likely to modify
gene function and have been linked to hundreds of Men-
delian disorders.1,2 However, the impact of PTVs on com-
plex traits has been limited by the available sample size
of whole-exome sequencing studies (WESs).3 Here, we
assembled whole-exome sequencing data from 100,296 in-
dividuals, drawing from a combination of cohort and case/
control disease studies with phenotypic information on a
total of 13 quantitative traits and 10 diseases (Tables
S1–S3). We used a common pipeline to process, annotate,
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Ethical committees for each study approved all procedures
and all subjects provided written informed consent (or
legal guardian consent and subject assent).
We began by focusing our analysis on PTVs that occur in
a set of 3,172 PTV-intolerant (PI) genes (see Table S4 for all
gene sets used in this study). Our motivation for focusing
on the PI-PTVs was two-fold. First, this gene class was iden-
tified through an unbiased approach that leveraged
the observed frequency distribution in ExAC4 without
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Figure 1. Variants Frequency Distribution across Different Ethnic Group and Gene Sets
(A) Average number of variants per individual in n ¼ 83,439 participants without neurodevelopmental/psychiatric disorders. We report
the results separately for each ethnic group.
(B) Ratio between PTV/Synonymous for each ethnic group.
Abbreviations: Afr, African American; Eas, East Asian; Sas, South Asian; Amr, Latinos; Nfe, non-Finnish European; Asj, Ashkenazi Jewish;
Fin, Finnish.experiments. Second, PI-PTVs have been shown to asso-
ciate with early-onset neurodevelopmental and psychiatric
disorders and are likely to result in reproductively disad-
vantageous phenotypes.5–7 To focus on those variants
that are most likely to be subject to purifying selection,
we considered only rare (allele frequency < 0.1%) and ul-
tra-rare (observed in fewer than 1 in 201,176 individuals)
variants (Supplemental Material and Methods).
After excluding participants diagnosed with a psychiat-
ric or neurodevelopmental disorder, we observed an
average of 7.72 and 0.30 rare PTVs per individual, across
all genes and in PI genes, respectively (Figure 1A); one or
more ultra-rare PI-PTV was observed in 11% of the individ-
uals. The number and frequency of rare variants differs
across populations, reflecting the degree of selection com-
pounded by recent demography, including bottlenecks,
split times, and migration between populations.8 The ratio
of deleterious to neutral alleles per individual increases as
humans migrated out of Africa, consistent with less effi-
cient negative selection against deleterious variants and se-
rial founder effects that reduce the effective populationThe Americasize.9 Conditional on a variant being ultra-rare, we observe
a higher ratio of PTVs to synonymous variants (Figure 1B);
recently arisen ultra-rare variants have had less time to be
purged by negative selection, which is further magnified
in populations that have undergone a recent bottleneck.
For example, we observed a higher ratio among Ashkenazi
Jewish and Finnish populations as compared to non-
Finnish Europeans, reflecting the more recent popula-
tion-specific bottlenecks.10,11
We tested the association between a burden of PI-PTVs
and the 13 traits and 10 disease diagnoses (Figure 2) by per-
forming study-specific and ethnicity-specific linear or
logistic regression analysis adjusting for potential con-
founders such as overall mutation rate (Table S5). The re-
sults of these separate analyses were then meta-analyzed
(Supplemental Material and Methods). We used an experi-
ment-wise p value threshold of 2 3 103 to account for
multiple testing (0.05/23 traits tested). Among the quanti-
tative traits, we found that carriers of at least one rare
PI-PTV had fewer years of education (2.2 months, p ¼
4 3 104), as we have previously reported,12 were shortern Journal of Human Genetics 102, 1204–1211, June 7, 2018 1205
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Figure 2. Association Analysis for Rare and Ultra-rare Variant Burden
(A) Association between PI-PTV burden and continuous traits. We reported the association in standard deviations (SD) to allow for com-
parison across traits. In parentheses, we reported the number of individual included in the analysis for each trait. The p values are re-
ported only for experiment-wise significant results (p < 2 3 103), highlighted in red. Bars indicate 95% confidence intervals. All the
results are obtained from meta-analyzing study and ethnicity-specific associations.
(B) Odds ratio for association between PI-PTV burden and dichotomous traits. In brackets, we reported the number of case and control
subjects.(0.2 cm, p ¼ 3 3 104), and were younger (3.7 months,
p ¼ 2 3 107).
To ensure the robustness of the age (at enrollment)
result, we performed a series of quality control analyses
to guard against the impact of technical confounders or
specific study designs that might bias the results. We first
confirm that the signal was not observed among PTVs in
non-PI genes and synonymous variants in PI genes, our
negative controls (Figure S2). We further found that the ef-
fect was consistent across ethnicities and study cohorts
(Figure S3), when INDELs and SNPs were considered sepa-
rately, when mutations possibly caused by cytosine deam-
ination (C>T or G>A) were excluded, and when a highly
stringent QC was used (Figure S4). Similarly, the associa-
tion did not change after adjusting for eight QC metrics
capturing most of the sample properties (Figure S5).
Although we could not exclude the impact of unmeasured
confounder, we find this result consistent with reduced
survival, detrimental health, or decreased study participa-
tion over time among PI-PTVs carriers. If reduced survival
or detrimental health effects drive this association, we
see it as a signature of viability selection, overall in the pop-
ulation. Analyses with time at death as the outcome will be
needed to confirm the interpretation of this finding.
We then focused on dichotomous traits (Figure 2). We
observed significant associations with all psychiatric disor-1206 The American Journal of Human Genetics 102, 1204–1211, Junders that were tested: intellectual disability (ID) (odds ratio
[OR]¼ 1.7, p¼ 43 108), autism (OR¼ 1.3, p¼ 13 1014),
schizophrenia (OR ¼ 1.2, p ¼ 5 3 108), ADHD (OR ¼ 1.2,
p ¼ 5 3 1010), and bipolar disorder (OR ¼ 1.2, p ¼ 8 3
104). We did not, however, find PI-PTV burden to be asso-
ciated with later-onset, non-brain-related diseases such as
type 2 diabetes, early-onset myocardial infarction, inflam-
matory bowel disease, ulcerative colitis, or Crohn disease.
Across all significantly associated phenotypes, the effect
size was stronger among the subset of ultra-rare PI-PTV car-
riers, confirming that rarer PTVs are, on average, more
deleterious.
The association with these five neurodevelopmental/
psychiatric disorders and three quantitative traits was
observed only for PI-PTVs and not for PTVs in non-PI genes
nor for synonymous variants in PI genes. These results sug-
gest that the association to PI-PTVs is not driven by popu-
lation stratification or technical bias (Figure S6).
Our approach so far focuses on assuming that all PI-PTVs
act on the phenotype in the same direction, that is, they
are all either protective or risk conferring. We relaxed
this hypothesis, allowing rare PI-PTVs to have different di-
rections as well as different magnitudes of effects, and
repeated these tests using SKAT.13 We did not identify
any additional associations (Figure S7), suggesting that
PI genes do not account for a substantial fraction ofe 7, 2018
variability in the traits for which no PTV burden was iden-
tified. Further, the observed burden of PI-PTVs for neurode-
velopmental/psychiatric disorders, height, educational
attainment, and age suggests that the majority of those
PI genes that have an effect, do so in the same direction.
Although case ascertainment bias reduces the power of de-
tecting protective variants, this is not the case for contin-
uous traits like height.
We also evaluated whether damaging missense variants,
which are on average more common and less severely dele-
terious than PTVs, showed a similar signal. Damaging
missense variants have been associated with complex dis-
orders such as coronary heart disease and inflammatory
bowel disease.14,15 We found an independent signal for
damaging missense variants in PI genes for all disorders
and traits that were also associated with PI-PTVs. Further-
more, the strength of the association increased as a
function of the number of prediction algorithms that
confidently classified a missense variant as ‘‘damaging’’
(Figure S8), suggesting that these missense mutations are
similar to PTVs in biological effect, potentially abrogating
gene function. We note that this effect was particularly
strong for ultra-rare variants, reinforcing the observation
that variant frequency is a marker of selection and aids in
the identification of pathogenic damaging missense varia-
tion.16,17
Given the high degree of shared comorbidities across
neurodevelopmental/psychiatric disorders, we leveraged
information from the Danish National Psychiatric registry
to evaluate whether the signal was driven by a specific dis-
order or shared across multiple disorders. Individuals with
multiple neurodevelopmental/psychiatric disorders, and
especially those with ID, showed a stronger enrichment
of PI-PTVs (Figure S9). Nevertheless, among those without
comorbidities, the signal remained significant and remark-
ably similar across disorders (OR¼ 1.12, 1.15, 1.21, 1.18 for
schizophrenia, bipolar, autism, and ADHD, respectively;
Cochran’s Q test for heterogeneity p ¼ 0.282). We further
found that carriers of ultra-rare PI-PTVs had earlier onset
of ADHD (4.0 months, p ¼ 0.008; Table S6). However,
this was partially explained by the fact that individuals
with earlier diagnosis of ADHD were also more likely to
be diagnosed with ID (14.7 versus 15.5 years for individ-
uals with ADHD with and without ID, t test p value ¼
0.009). Indeed, when we considered ADHD-affected case
subjects without major comorbidities, the effect was atten-
uated (2.9 months, p ¼ 0.12). Finally, in control subjects
with none of these psychiatric diagnoses, we still observed
a significant association with the broader ICD-10 category
of mental, behavioral, and neurodevelopmental disorders,
suggesting that PI-PTVs influence the broader cognitive
spectrum (Table S7).
Since previous studies have shown a higher rate of PI de
novo PTVs in autism-affected females as compared to
males,18,19 we wondered whether sex played a role here.
In this study, however, we did not have parent-offspring
subjects needed to distinguish de novo variants from thoseThe Americathat have recently arisen in the population, the latter being
the majority of observed rare variants. This would poten-
tially dilute the sex-specific effect if it is in fact a property
of de novo variants but not of rare variants more generally.
We found both weak and insignificant differences between
males and females in the effect of PI-PTVs on four neurode-
velopmental/psychiatric disorders (Table S8). Interestingly,
we did not observe differences in ADHD-affected males
and females, in contrast with the hypothesis that affected
females might be enriched for rare deleterious variants.20
We cannot exclude that differences in the diagnostic
criteria used in these European studies compared to those
of previous studies, which were mostly conducted in the
U.S., might explain these results.
We also assessed whether the observed burden of PTVs
was specific to PI genes or whether such a burden could
be identified for other gene sets that are likely to contain
functionally relevant genes. First, we examined other
experimental and literature-based gene sets linked to se-
vere phenotypes. Specifically, we considered all genes
(1) reported in ClinVar,2 (2) that resulted in lethal or subvi-
able phenotypes in mice,21 (3) that were required for pro-
liferation and survival in a human cancer cell line,22 and
(4) were categorized as haploinsufficient by ClinGen
(Table S4 and Supplemental Material andMethods). Except
for the haploinsufficient genes, which showed a signifi-
cantly stronger association with autism alone, none of
the other gene sets tested showed the PTV burden that
was captured by PI genes (Figure S10). This suggests that
the degree of natural selection against PTVs in a gene is
indeed an important indicator of whether such PTVs are
likely to be implicated as strong effects for neurodevelop-
mental/psychiatric disorders, height, educational attain-
ment, and age. It also highlights that observed associations
are not simply reflecting an aggregate signal from known
Mendelian disorders. Indeed, we could not detect signifi-
cant association for any of the traits considered in this
analysis when focusing on just ClinVar genes.
We reasoned that a single variant approach, rather than
a gene-based test, might provide increased resolution. We
considered all high-quality ClinVar variants (0.76 on
average per individual) and a set of variants deemed to
be recessive lethal (0.03) (Supplemental Material and
Methods). Carriers of these variants were not enriched in
any of the disorders or traits examined here (Table S9).
Second, we examined whether results from GWASs con-
ducted on the same phenotypes as those included in this
study could implicate genes containing an aggregate PTV
burden. We used DEPICT23 to link genome-wide signifi-
cant hits to candidate genes (Table S10 and Supplemental
Material and Methods) and, within each GWAS-derived
gene set, we studied the association between rare PTVs
and the phenotypes using the SKAT test. GWAS-derived
gene-sets captured associations between rare PTVs and
different classes of lipids (Figure 3 and Table S11). For
example, the association between rare PTVs and HDL
cholesterol was captured by gene sets derived from GWASsn Journal of Human Genetics 102, 1204–1211, June 7, 2018 1207
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Figure 3. Signal Overlap between Rare Variants and GWAS-Derived Gene Sets
(A) Association (SKAT test p value) in GWAS-derived gene sets (y axis) between rare PTVs and the phenotypes reported on the x axis. Each
gene set is obtained using DEPICT to link SNPs derived from GWAS with p value < 53 108 and a candidate gene. In brackets we report
the number of genes with at least one PTV in our dataset. p values are reported only for experiment-wise associations (p < 0.0003).
(B) Association (SKAT test p value) in GWAS-derived gene sets (y axis) between rare PTVs þ damaging missense and the phenotypes re-
ported on the x axis.of HDL (p¼ 23 109), total cholesterol (p¼ 33 108), and
triglycerides (p ¼ 4 3 109), but not by those of coronary
heart diseases (p¼ 0.25), consistent with previous observa-
tions about non-causality of HDL cholesterol on coronary
heart diseases.24 The inclusion of both rare damaging
missense and PTVs resulted in additional signal co-localiza-
tion between inflammatory bowel disease, early-onset
myocardial infarction, and the corresponding GWAS-
derived gene sets. However, it appeared that all these
signals were being driven by well-known genes, involved
in rare familial forms of these diseases. Specifically, when
Mendelian lipid genes and NOD2 were removed from
the cardiovascular and inflammatory bowel disease-
related GWAS gene sets, respectively, no signal remained
(Figure S11). This might reflect a lack of power (despite
this being the largest WES study for the majority of the
traits), inaccurate links between genome-wide significant
hits and the corresponding candidate genes or PTVs, and
common variants acting on partially distinct pathways.
Nevertheless, we observed similar results when including
SNPs below genome-wide significance to increase power
and when using different methods to link SNPs with corre-
sponding candidate genes to increase precision, including
gene-based testing25 and eQTL mapping (Figure S11 and
Supplemental Material and Methods).
The choice of the 10 diseases and 13 quantitative traits
included in the main analysis was driven by data availabil-
ity and power considerations but was not truly unbiased.
Therefore, we leveraged national population health regis-
tries to increase the scope of disorders we could examine.
Thesewell-studied and validated registries26,27 include diag-
nostic codes from 14,117 individuals (n ¼ 8,493 from1208 The American Journal of Human Genetics 102, 1204–1211, JunFinland and 5,624 from Sweden), recorded between 1968
and 2015 (Table S12). Individuals with psychiatric disorders
were excluded from our analyses. To maximize the validity
of the diagnoses, we used a curated list of disease definitions
aggregating related ICD codes (Table S13). We studied the
association between rare PI-PTVs and 101 diseases with
at least 50 case subjects, using a survival analysis model.
We identified an association (multi-testing significance
threshold¼ 0.05/101; 53 104) with chronic kidney failure
(hazard ratio¼ 1.9, p¼ 33 106; number of case subjects¼
120; Figure S12). The association was strong among the
Finnish data and only significant when considering ultra-
rare PI-PTVs in the Swedish data (Table S14).
We speculated that this association might reflect a
burden of underlying comorbidities that were too rare to
be included in this analysis. To evaluate epidemiological
associations, we extended our analysis to 28,709 Finnish
individuals that were not exome sequenced but were
linked to the registries. We found that individuals with
chronic kidney failure also have a higher rate of cardiovas-
cular-related comorbidities, as well as skin infections, kid-
ney cancer, and other abnormalities of the renal system
(Table S15). Therefore, it is challenging to determine
whether it is the chronic kidney failure or some more
rare comorbid condition that drives the association with
PI-PTVs. Nevertheless, five PI-PTVs in Finnish individuals
with chronic kidney failure were in genes involved inMen-
delian-type disorders characterized by renal or endocrine
abnormalities (ARNT2, COL4A1, DMXL2, FBN1, and
NNT; Supplemental Material and Methods).
We also examined whether the association between PI-
PTVs and diminished cognition and detrimental healthe 7, 2018
would result in a higher number of hospital visits, count-
ing the number of in-patient visits associated with a
unique ICD codes. In both the Swedish and Finnish data-
sets, we observed a significant increase in the rate of hospi-
tal visits with a greater burden of PI-PTVs (þ7.6% per addi-
tional PI-PTV, p ¼ 0.0002). We used different strategies to
model the outcome and observed similar results (Table
S16 and Figure S13).
By aggregating WES data on more than 100,000 individ-
uals for 23 different traits and disorders, we have gained
insight into the role of PTVs in conferring risk for these
conditions. First, PTVs occurring in PI genes had a remark-
ably similar effect on autism, schizophrenia, bipolar disor-
der, and ADHD. The majority of this signal was driven by
ultra-rare PI-PTVs and we observed only a marginal addi-
tional contribution of non-ultra-rare PTVs with allele
frequency < 0.1% (Figure S14). The observed effects of
PI-PTVs on psychiatric disorders were not driven by major
underlying comorbidities. This suggests that these PI-PTVs
as a whole are likely to be pleiotropic, influencing some
core intermediate phenotypes that relate to risk across
many psychiatric disorders. Nevertheless, we could
consider only ‘‘bulk’’ pleiotropy, which is the combined
impact of PTVs in PI genes, and we are not powered to
detect whether single variants have disease-specific effects.
Further, this burden suggests that individual PI genes will
be eventually discovered conclusively for each of these dis-
orders, not just autism, but that such associations will need
to be interpreted in the light of this shared effect across dis-
orders. The strong enrichment of PI-PTVs in individuals
with neurodevelopmental/psychiatric disorders does not
exclude the existence of non-PI genes involved in the eti-
ology of these disorders. These genes, however, are more
likely to have weaker and, possibly, trait-specific effect.
Second, we detected a significant association between
PI-PTVs and decreased human height. In contrast to
this, a recent large-scale study using the exome chip has
shown a similar numbers of height-increasing and
height-decreasing rare variants.28 This discrepancy could
be because, by using a more stringent frequency cut-off
and focusing on a subset of genes likely to cause early-
onset severe disease, we effectively considered variants
related to a burden of (incompletely) penetrant Mende-
lian-type disorders, often characterized by reduced
growth. Such an interpretation is consistent with a tighter
link to directional selection on stronger impact mutations
for human height.
Third, we systematically compared the co-localization
of signal between GWAS-candidate genes and rare PTVs.
We found few overlaps (cardiovascular-related traits, in-
flammatory bowel disease) which, we revealed, were
entirely driven by a few genes previously identified by
both GWASs and WES studies. Other traits did not show
any overlap. Schizophrenia, for example, which is highly
enriched for PI-PTVs, did not show overlap with GWAS
candidate genes. Even among traits where genes with
low-frequency coding variants have been previously iden-The Americatified by exome-chip-based studies, such as height and
systolic blood pressure, we found no substantial rare
PTVs enrichment. These results suggest that the relation-
ship between GWAS signal and rare coding variants is
not always straightforward, and that, when interpreting
WES data, other complementary approaches such as those
that integrate population genetic models and large sample
resources might be more suitable to nominate gene sets of
interest. The degree of overlap, and therefore the most
effective strategy to identify pathogenic variants, is likely
to depend on the selective pressure shaping the genetic ar-
chitecture of the trait under investigation. Moreover, it
cannot be overlooked that individuals carrying rare PTVs
in genes implicated by common variant-based approaches
might present phenotypic outcomes that deviate from
those under investigation. Finally, it is interesting to
notice that, while PTVs tend to have a consistent direc-
tional effect within a PI gene, this is not the case for
GWAS-derived gene sets, where most of signals could be
captured only by assuming heterogeneity in effect direc-
tion (Supplemental Material and Methods).
In conclusion, in this large WES study, we showed that
PI genes are well suited to capture the impact of rare to ul-
tra-rare PTVs on the cognitive, behavioral, and develop-
mental spectra. This is less the case for major later-onset
complex traits with modest effect on reproductive fitness.
Strategies to prioritize gene sets relevant for these traits
would need to consider the role that relaxed selective pres-
sure has been playing in shaping the frequency distribu-
tion of disease-causing PTVs.Accession Numbers
We have made the code and variants used in the paper available at
https://github.com/andgan/ultra_rare_pheno_spectrum.
We are extremely committed to data sharing. However, we
recognize that due to national regulation, not all individual-level
data and phenotypes can be shared using dbGap. Specifically, ac-
cess to the Danish and Finnish phenotypic and genetic data can
be obtained only by Danish and Finnish national institutions. In-
formation about getting access to the Danish data can be obtained
at http://ipsych.au.dk/about-ipsych/. Access to the Finnish data
can be obtained at https://www.thl.fi/en/web/thl-biobank/
for-researchers. We are happy to help other researchers with
information to simplify the application process to obtain
these datasets. All the remaining datasets are available via
dbGap, as follows. Migen: phs000814.v1.p1, phs000902.v1.p1,
phs000917.v1.p1, phs000883.v1.p1, phs001058.v1.p1, phs000806.
v1.p1, phs001000.v1.p1, phs000990.v1.p1, phs000916.v1.p1,
phs001101.v1.p1; T2D-GENES/GoT2D/SIGMA: phs001099,
phs001098, phs000849, phs001097, phs001096, phs001095,
phs001093, phs001100, phs001102, phs000840; Swedish Schizo-
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